A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis group B outer membrane protein produces protective antibodies against gram-negative bacteremia

被引:47
作者
Bhattacharjee, AK
Opal, SM
Taylor, R
Naso, R
Semenuk, M
Zollinger, WD
Moran, EE
Young, L
Hammack, C
Sadoff, JC
Cross, AS
机构
[1] BROWN UNIV,SCH MED,PROVIDENCE,RI 02912
[2] UNIVAX BIOL INC,ROCKVILLE,MD
关键词
D O I
10.1093/infdis/173.5.1157
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Earlier studies showed that purified IgG from sera of rabbits immunized with a boiled Escherichia coli J5 (Re chemotype) whole cell vaccine protected neutropenic rats against gram-negative bacterial sepsis, In the present study, de-O-acylated J5 lipopolysaccharide (J5 DLPS) as a noncovalent complex with Neisseria meningitidis group B outer membrane protein (GBOMP) elicited anti-J5 LPS antibodies in rabbits, IgG prepared from immune rabbit sera protected neutropenic rats against lethal challenge with Pseudomonas aeruginosa 12:4:4 (Fisher Devlin immunotype 6), Sixteen of 26 rats treated with the postimmune serum IgG were protected compared with none of 20 rats treated with the control rabbit serum IgG (P <.001), In vitro binding studies showed binding of anti-J5 IgG to several gram-negative bacteria, These results indicate that a subunit vaccine made of J5 DLPS as a noncovalent complex with GBOMP may protect against gram-negative bacteremia.
引用
收藏
页码:1157 / 1163
页数:7
相关论文
共 35 条
  • [1] Ashcroft M T, 1967, Lancet, V2, P1056
  • [2] AFFINITY-PURIFIED ESCHERICHIA-COLI J5 LIPOPOLYSACCHARIDE-SPECIFIC IGG PROTECTS NEUTROPENIC RATS AGAINST GRAM-NEGATIVE BACTERIAL SEPSIS
    BHATTACHARJEE, AK
    OPAL, SM
    PALARDY, JE
    DRABICK, JJ
    COLLINS, H
    TAYLOR, R
    COTTON, A
    CROSS, AS
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (03) : 622 - 629
  • [3] ANTIBODIES TO MENINGOCOCCAL H.8(LIP) ANTIGEN FAIL TO SHOW BACTERICIDAL ACTIVITY
    BHATTACHARJEE, AK
    MORAN, EE
    ZOLLINGER, WD
    [J]. CANADIAN JOURNAL OF MICROBIOLOGY, 1990, 36 (02) : 117 - 122
  • [4] BHATTACHARJEE AK, 1975, J BIOL CHEM, V250, P1926
  • [5] A CONTROLLED CLINICAL-TRIAL OF HIGH-DOSE METHYLPREDNISOLONE IN THE TREATMENT OF SEVERE SEPSIS AND SEPTIC SHOCK
    BONE, RC
    FISHER, CJ
    CLEMMER, TP
    SLOTMAN, GJ
    METZ, CA
    BALK, RA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (11) : 653 - 658
  • [6] IMMUNIZATION AGAINST NOSOCOMIAL INFECTION
    BRAUDE, AI
    ZIEGLER, EJ
    MCCUTCHAN, JA
    DOUGLAS, H
    [J]. AMERICAN JOURNAL OF MEDICINE, 1981, 70 (02) : 463 - 466
  • [7] BRAUDE AI, 1972, J IMMUNOL, V108, P505
  • [8] CHEDID L, 1968, J IMMUNOL, V100, P292
  • [9] ORAL CIPROFLOXACIN AND A MONOCLONAL-ANTIBODY TO LIPOPOLYSACCHARIDE PROTECT LEUKOPENIC RATS FROM LETHAL INFECTION WITH PSEUDOMONAS-AERUGINOSA
    COLLINS, HH
    CROSS, AS
    DOBEK, A
    OPAL, SM
    MCCLAIN, JB
    SADOFF, JC
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (06) : 1073 - 1082
  • [10] EVALUATION OF IMMUNOTHERAPEUTIC APPROACHES FOR THE POTENTIAL TREATMENT OF INFECTIONS CAUSED BY K1-POSITIVE ESCHERICHIA-COLI
    CROSS, AS
    ZOLLINGER, W
    MANDRELL, R
    GEMSKI, P
    SADOFF, J
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1983, 147 (01) : 68 - 76